Fig. 1

Details of the different study phases.  ^aA Medtronic 780G investigational device has the autocorrection algorithm found in a 780G device together with similar glucose target settings and external features as a commercial Medtronic 780G device, together with use of a Guardian 3 sensor. During this phase participants continued their prior insulin dose settings with weekly upload to Cloud and clinician review.  ^bA Medtronic 780G investigational device has the autocorrection algorithm found in a 780G device together with similar glucose target settings and external features, together with use of a Guardian 3 sensor, similar to a commercial Medtronic 780G device. ^cDue to staggered recruitment of participants over several months, some participants remained in a holding pattern on investigational 780G for longer than 8 weeks in phase 1 until enrolment was complete and participants were ready to move to phase 2. In this period optimisations were provided and reviewed for safety(impact on hypoglycaemia) by the multidisciplinary team prior.